Sight Sciences

$21.50 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Sight Sciences

Sight Sciences, Inc. is an ophthalmic medical device company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company’s surgical glaucoma product portfolio features the OMNI surgical system (OMNI), a device that facilitates the performance of both trabeculotomy and canaloplasty with a single device and single corneal incision. Its nonsurgical dry eye product portfolio consists of the TearCare system for ophthalmologists and optometrists. TearCare is a wearable eyelid technology that delivers targeted and adjustable heat to the meibomian glands of the eyelids. The Company has two reportable segments: Surgical Glaucoma and Dry Eye. Its Surgical Glaucoma segment consists of sales of the OMNI surgical system. Its Dry Eye segment includes sales of the TearCare system and related components and accessories. The Company primarily sell both the systems through a direct sales model.

Stock Analysis

last close $21.5
1-mo return -25.3%
3-mo return -35.8%
avg daily vol. 239.41T
52-week high 42.57
52-week low 21.19
market cap. $1.0B
forward pe -
annual div. -
roe -
ltg forecast -
dividend yield -
annual rev. $39M
inst own. 41.3%
baraka

Subscribe now for daily local and international financial news

Subscribe